These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28547856)

  • 1. Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.
    Berardi R; Torniai M; Pusceddu S; Spada F; Ibrahim T; Brizzi MP; Antonuzzo L; Ferolla P; Panzuto F; Silvestris N; Partelli S; Ferretti B; Freddari F; Gucciardino C; Testa E; Concas L; Murgioni S; Bongiovanni A; Zichi C; Riva N; Rinzivillo M; Brunetti O; Giustini L; Di Costanzo F; Delle Fave G; Fazio N; De Braud F; Falconi M; Cascinu S
    Cancer Med; 2017 Jul; 6(7):1493-1499. PubMed ID: 28547856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus for advanced pancreatic neuroendocrine tumors.
    Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
    N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
    Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
    Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
    J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).
    Vernieri C; Pusceddu S; Fucà G; Indelicato P; Centonze G; Castagnoli L; Ferrari E; Ajazi A; Pupa S; Casola S; Foiani M; Mazzaferro V; Pruneri G; Milione M; de Braud F
    Int J Cancer; 2019 Apr; 144(7):1704-1712. PubMed ID: 30520016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
    Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
    Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.
    Lee KJ; Cho JH; Lee SH; Song SY; Lee KH; Jeong S; Ryu JK; Woo SM; Bang S; Lee JK; Lee TH; Paik WH; Kim YT; Lee WJ
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):799-805. PubMed ID: 28884280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
    Chan JA; Blaszkowsky L; Stuart K; Zhu AX; Allen J; Wadlow R; Ryan DP; Meyerhardt J; Gonzalez M; Regan E; Zheng H; Kulke MH
    Cancer; 2013 Sep; 119(17):3212-8. PubMed ID: 23733618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
    Viúdez A; Crespo G; Gómez Dorronsoro ML; Arozarena I; Marín-Méndez JJ; Custodio A; Benavent M; Goñi S; García-Paredes B; Hernando J; Durantez M; Alonso V; Riesco MDC; López C; Jiménez-Fonseca P; San Vicente BL; González-Borja I; Sevilla I; Hernández-Garcia I; Carmona-Bayonas A; Capdevila J; Pérez-Sanz J; García-Carbonero R; Pérez-Ricarte L; Llanos M; Vera R; De Jesús Acosta A
    Pancreatology; 2021 Jan; 21(1):215-223. PubMed ID: 33358592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.
    Yao J; Wang JY; Liu Y; Wang B; Li YX; Zhang R; Wang LS; Liu L
    Med Oncol; 2014 Dec; 31(12):251. PubMed ID: 25395378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptomatic Control of Neuroendocrine Tumours with Everolimus.
    Bainbridge HE; Larbi E; Middleton G
    Horm Cancer; 2015 Dec; 6(5-6):254-9. PubMed ID: 26245686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
    Yao JC; Lombard-Bohas C; Baudin E; Kvols LK; Rougier P; Ruszniewski P; Hoosen S; St Peter J; Haas T; Lebwohl D; Van Cutsem E; Kulke MH; Hobday TJ; O'Dorisio TM; Shah MH; Cadiot G; Luppi G; Posey JA; Wiedenmann B
    J Clin Oncol; 2010 Jan; 28(1):69-76. PubMed ID: 19933912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms.
    Lee L; Ito T; Igarashi H; Ueda K; Fujiyama T; Kawabe K; Ogawa Y
    J Hepatobiliary Pancreat Sci; 2017 Feb; 24(2):95-102. PubMed ID: 27926987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic neuroendocrine neoplasms.
    Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
    Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.
    Ma ZY; Gong YF; Zhuang HK; Zhou ZX; Huang SZ; Zou YP; Huang BW; Sun ZH; Zhang CZ; Tang YQ; Hou BH
    World J Gastroenterol; 2020 May; 26(19):2305-2322. PubMed ID: 32476795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
    Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
    Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.
    Kulke MH; Ruszniewski P; Van Cutsem E; Lombard-Bohas C; Valle JW; De Herder WW; Pavel M; Degtyarev E; Brase JC; Bubuteishvili-Pacaud L; Voi M; Salazar R; Borbath I; Fazio N; Smith D; Capdevila J; Riechelmann RP; Yao JC
    Ann Oncol; 2017 Jun; 28(6):1309-1315. PubMed ID: 28327907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.